A Randomized MRI-Based Study Reveals VasQ External Support Promotes More Stable Hemodynamics than Standard AVFs

Dr. Andrea Remuzzi and his research team at The University of Bergamo have recently published a randomized-controlled MRI-based computational fluid dynamic study in the Journal of Vascular Access that revealed the impact of VasQ™ External Support on fistula morphology and flow.

VasQ External Support, a Laminate Medical Technologies device is implanted around the connection between the vein and artery during the creation of an arteriovenous fistula (AVF) for hemodialysis patients with the intent to provide structural reinforcement and promote a more stable flow profile.

The MRI study confirmed the device retained a more optimal geometric configuration over the 1-year study period, which promoted a more stable hemodynamic profile. Control patients on the other hand, experienced significant morphological changes, such as atrial “tenting” and angular degradation, that resulted in either an aneurysmal or stenotic AVF with a less stable flow profile.

Dr. Remuzzi stated that, “Morphology is an important surgical consideration to create favorable hemodynamics for fistula maturation and long-term success. Our initial results demonstrated that implanting the VasQ External Support during creation surgery can retain the desired fistula morphology over the long-term that otherwise maybe negatively altered as the tissue undergoes remodeling.”

Several clinical studies conducted in Europe and the U.S. have described an increase in the rate of fistula maturation to become usable for hemodialysis.1-4 However, Dr. Remuzzi’s study was the first of its kind to demonstrate the potential structural and hemodynamic effect of VasQ that may explain the consistent beneficial clinical outcomes that have been reported to date.

Tammy Gilon, Co-founder and CEO of Laminate, commented, “Seeing the vision my co-founder, Eyal Orion, and I had for the device when we first designed it ten years ago come to fruition in patients is a major milestone for Laminate. We appreciate the scientific rigor and expertise Dr. Remuzzi and his team provided in elucidating how VasQ works to create more usable fistulas.”

To date, Laminate has CE mark and has submitted for market clearance in the U.S. to the FDA.

The full publication is now available for open access at Journal of Vascular Access.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”